Speakers at American Society of Health-System Pharmacists (ASHP) Pharmacy Futures 2024 discuss the significant increase in published clinical literature during and after the COVID-19 pandemic, and the evolving role and reliability of AI tools such as ChatGPT in providing accurate medical information.
Donanemab was able to significantly slow clinical progression of Alzheimer disease and amyloid and tau pathology at 76 weeks of treatment.
The 4-in-1 respiratory diagnostic test is either a single nasopharyngeal or anterior nasal swab that can confirm or rule out SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus with a single test.
At ASHP Pharmacy Futures 2024, Casey Olsen, PharmD, explains that AI can affect patient trust in providers, with implications for the importance of learning to balance use of technology with human elements in clinical settings.
At the ASHP Pharmacy Futures 2024 conference, Scott D. Nelson, PharmD, MS, ACHIP, FAMIA, discusses research showed that although AI models can significantly enhance diagnostic accuracy, they can also exacerbate existing disparities.
Kenneth A. Richman, PhD, discusses the disruptive nature of artificial intelligence (AI) in health care, highlighting both its transformative potential and the ethical considerations of governability and sustainability in its implementation.
The impact of artificial intelligence (AI) on health care is growing, from diagnostics to drug discovery.
The expanded indication is for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in adults aged 50 through 59 years who are at an increased risk.
Patients with undiagnosed asthma or COPD who received usual care from their primary providers were more likely to visit the hospital or specialists because of respiratory illness.
To qualify for therapy, patients must be screened for type 1 diabetes islet autoantibodies when they are asymptomatic, which requires better education on screening opportunities.
Compared to other cases, the most recent patient reported more flu-like symptoms, including cough, congestion, watery eyes, and sore throat.
Serotypes associated with V116 (Merck & Co. Inc.) had higher clinical and economic burden for individuals with invasive pneumococcal disease.
A single dose of the vaccine showed long-lasting protection against RSV-associated lower respiratory tract disease in older adults.
Imetelstat (Rytelo; Geron Corp) is a first-in-class telomerase inhibitor.
According to investigators, the primary and key secondary end points were met during the 52-week placebo-controlled period of the trial.
Five medications (tramadol, olanzapine, mirtazapine, bupropion, and atomoxetine) were associated with significantly better OUD remission.
Molly McGraw, PharmD, BCPS, manager of clinical pharmacy at UPMC Health Plan and Kim Castelnovo, RPh, Pharmacy Manager at Community Care Behavioral Health Organization, talk about the importance of mental health care for patients.
Over the course of 15 years, epigenetic and transcriptional analysis of postmortem brain samples have revealed underlying molecular differences.
Expert discusses the challenges faced by pharmacists in palliative and hospice care.
Data show women with poor cardiovascular health may have an increased risk of early signs of cognitive decline in midlife.
Data from the PERSEUS trial supports use of daratumumab in combination with bortezomib, lenalidomide, and dexamethasone followed by daratumumab and lenalidomide maintenance as a new standard of care for patients with newly diagnosed multiple myeloma.
Results from the initial safety run-in of MajesTEC-7 indicate that the combination of teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma (NDMM) shows a manageable safety profile with early signs of efficacy.
Daratumumab in combination with standard treatment regimens shows benefit in multiple myeloma.
Providers, the community, health systems, and health policies can all play a part in addressing various challenges in care for obesity.
Patients with sickle cell disease with more than a 6-month delay transitioning from pediatric to adult care were about twice as likely to be hospitalized.
Data analysis can help hospitals address waste of controlled substances that fuels diversion and increased costs.
Data presented at ASCO 2024 show fam-trastuzumab deruxtecan-nxki (T-DXd) delayed cancer growth in patients with hormone receptor-positive (HR+), HER2-low or -ultralow disease that progressed following endocrine therapy (ET).
Results from the trial provide evidence bolstering ASCO’s clinical practice guideline supporting the integration of early palliative care into standard oncology practice.
This is the largest dataset of pregnancy outcomes for an anti-CD20 therapy in MS, enabling a more comprehensive understanding of ocrelizumab’s safety.
